Department of Audiology, School of Rehabilitation, Tehran University of Medical Science; and Department of Infectious Diseases and Tropical Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Otol Neurotol. 2022 Oct 1;43(9):e944-e950. doi: 10.1097/MAO.0000000000003649. Epub 2022 Aug 17.
Concerns about ototoxic and vestibulotoxic effects have been raised with the use of antiviruses in the treatment of COVID-19. This study aimed to determine the effect of hydroxychloroquine (HCQ) and examine the auditory system and its associated auditory and vestibular symptoms in patients with COVID-19.
Prospective study.
Thirty patients with a history of HCQ (HCQ+) and 30 patients without drug use (HCQ-), and 30 healthy adults as the control group participated.
Audiological assessments and evaluation of audio-vestibular symptoms. Evaluations were also repeated 1 month later.
Both HCQ+ and HCQ- groups showed poor pure-tone audiometry (PTA) thresholds and decreased transient evoked otoacoustic emission amplitudes at high frequencies in comparison to the healthy group. Despite the lack of significant differences in PTA between the two groups of patients, the differences in transient evoked otoacoustic emission amplitudes were significant. PTA thresholds and otoacoustic emission showed improvement after 1 month. Dizziness was the most common symptom that was reduced after 1 month.
Slight hearing loss was seen in patients with COVID-19 with or without HCQ. Also, hearing thresholds in the HCQ+ group did not show a significant difference compared with the HCQ- group. Nevertheless, it seems that more damage is done to the hair cells of patients with HCQ intake than in other patients. Hence, the ototoxicity effect of high doses of HCQ use in the COVID-19 patients should be considered. A relative improvement in the hearing was seen over time in both patient groups.
由于担心 COVID-19 治疗中使用抗病毒药物会产生耳毒性和前庭毒性，因此人们对此提出了担忧。本研究旨在确定羟氯喹（HCQ）的作用，并检查 COVID-19 患者的听觉系统及其相关的听觉和前庭症状。
前瞻性研究。
30 例有 HCQ 用药史的患者（HCQ+）和 30 例无药物使用史的患者（HCQ-），以及 30 例健康成年人作为对照组参与。
听力学评估和听觉-前庭症状评估。1 个月后重复评估。
与健康组相比，HCQ+和 HCQ-组的纯音听阈（PTA）阈值较差，高频瞬态诱发耳声发射幅度降低。尽管两组患者的 PTA 无显著差异，但瞬态诱发耳声发射幅度的差异具有统计学意义。1 个月后 PTA 阈值和耳声发射均有所改善。头晕是最常见的症状，1 个月后减轻。
COVID-19 患者无论是否使用 HCQ，均出现轻度听力损失。此外，HCQ+组的听力阈值与 HCQ-组相比无显著差异。然而，HCQ 摄入患者的毛细胞似乎比其他患者受到更大的损害。因此，应考虑 COVID-19 患者大剂量使用 HCQ 的耳毒性作用。两组患者的听力均随时间逐渐改善。
